Citation Information :
Annamalai MM, Sankaran A, Sarkar S. Fluoxetine-induced Kleptomania in a Patient with Depressive Disorder: A Case Report. 2019; 2 (4):156-157.
Kleptomania is a disorder wherein the individual has an irresistible urge/impulse to steal things that are usually not of monetary value. Selective serotonin receptor inhibitors (SSRIs) are usually the first-line treatment of depressive disorders. Reports of depressed patients experiencing symptoms of kleptomania after administration of SSRI have been few. Here we present such a case of a female patient who exhibited symptoms of kleptomania following treatment with fluoxetine, an SSRI.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed., Washington, D.C: American Psychiatric Association; 2013. p. 947.
Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock's synopsis of psychiatry: behavioral sciences/clinical psychiatry. 11th ed., Philadelphia: Wolters Kluwer; 2015. p. 1472.
McElroy SL, Hudson JI, Pope HG, Keck PE. Kleptomania: clinical characteristics and associated psychopathology. Psychol Med 1991;21(1):93–108. DOI: 10.1017/s0033291700014690.
Grant JE, Kim SW. Clinical characteristics and associated psychopathology of 22 patients with kleptomania. Compr Psychiatry 2002;43(5):378–384. DOI: 10.1053/comp.2002.34628.
Kindler S, Dannon PN, Iancu I, Sasson Y, Zohar J. Emergence of kleptomania during treatment for depression with serotonin selective reuptake inhibitors. Clin Neuropharmacol 1997;20(2): 126–129. DOI: 10.1097/00002826-199704000-00003.
Gupta PR. Emergence of kleptomania during treatment for obsessive compulsive disorder with fluvoxamine. Indian J Psychiatry 2014;56(1):100–101. DOI: 10.4103/0019-5545.124741.
Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007;113(2):296–320. DOI: 10.1016/j.pharmthera.2006.08.004.
Lepkifker E, Dannon PN, Ziv R, Iancu I, Horesh N, Kotler M. The treatment of kleptomania with serotonin reuptake inhibitors. Clin Neuropharmacol 1999;22(1):40–43. DOI: 10.1097/00002826-199901000-00008.